Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 7,459 matching trials from the live ClinicalTrials.gov search.
Conditions
Liver Transplantation, Ischemia/Reperfusion Injury, Oxidative Injury
Interventions
Nitric Oxide
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 69 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Brain Edema, Stroke, Acute
Interventions
BIIB093, Placebo
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 59 more
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more
Conditions
Unresectable Metastatic Colo-rectal Cancer
Interventions
Chemoembolization with irinotecan Bead, Irinotecan
Procedure · Drug
Lead sponsor
Generic Devices Consulting, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Aurora, Colorado • Chicago, Illinois • Burlington, Massachusetts
Conditions
Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction
Interventions
Relatlimab + Nivolumab, Nivolumab, Paclitaxel, Ramucirumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Daphne, Alabama • Bakersfield, California • Fullerton, California + 17 more
Completed Not applicable Interventional Results available

Hybrid L24 New Enrollment Post Approval Study

NCT02379819
Conditions
High Frequency Sensorineural Hearing Loss
Interventions
Nucleus Hybrid L24 Implant
Device
Lead sponsor
Cochlear
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
19
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 15 more
Conditions
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
815
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 511 more
Conditions
Sleep, Anxiety, Depression, Pain
Interventions
fsCBD Cannabidiol, Placebo, bsCBD Cannabidiol
Drug
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
25 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Pitt Hopkins Syndrome
Interventions
NNZ-2591
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
3 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 2 more
Conditions
Cervical Carcinoma, Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Stage I Uterine Corpus Cancer AJCC v7, Stage I Vaginal Cancer AJCC v6 and v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Cervical Cancer AJCC v6 and v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7, Stage III Uterine Corpus Cancer AJCC v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Vaginal Carcinoma
Interventions
Adavosertib, Cisplatin, External Beam Radiation Therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Sacramento, California • Aurora, Colorado • Lexington, Kentucky + 2 more
Conditions
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
493
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more
Conditions
Breast Cancer, Hot Flashes, Menopausal Symptoms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
flaxseed, placebo
Dietary Supplement · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
107
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 71 more
Conditions
Contraception
Interventions
ESS505 (BAY1454033)
Device
Lead sponsor
Bayer
Industry
Eligibility
21 Years to 44 Years · Female only
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
17
States / cities
Aurora, Colorado • Denver, Colorado • Wellington, Florida + 14 more
Conditions
Infertility
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
13
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 10 more
Conditions
Cancer Survivor
Interventions
Cognitive Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
25 Years to 34 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
326
States / cities
Fairbanks, Alaska • Fort Smith, Arkansas • Anaheim, California + 221 more
Conditions
Liver Disease
Interventions
HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate), Hepatic Venous Pressure Gradient (HVPG)
Drug · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Allergic Contact Dermatitis
Interventions
Panels 1.3, 2.2 and 3.2 experimental allergens
Diagnostic Test
Lead sponsor
Allerderm
Industry
Eligibility
6 Years to 17 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
San Diego, California • Aurora, Colorado • Louisville, Kentucky + 1 more
Conditions
Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IA Ovarian Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IB Ovarian Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage IC Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7
Interventions
Bevacizumab, Capecitabine, Carboplatin, Laboratory Biomarker Analysis, Oxaliplatin, Paclitaxel, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
248
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 163 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Integrated Care, Standard Therapy
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Conditions
Acute Coronary Syndrome
Interventions
Darapladib 160 mg, Placebo, Standard Therapy
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
13,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
290
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 252 more
Not listed No phase listed Observational Accepts healthy volunteers

Healthy Starts: Repeated Exposure Pilot

NCT05639361
Conditions
Feeding Behavior
Interventions
Repeated Exposure
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Months to 12 Months
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
28
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 21 more
Active, not recruiting Phase 2 Interventional

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

NCT05458674
Conditions
Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Interventions
Tucatinib, Eribulin, Trastuzumab
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Albuquerque, New Mexico + 3 more
Conditions
Haemophilia A, Haemophilia B
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 21 Years · Male only
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • San Diego, California + 19 more